Compare 10X Genomics Inc (TXG) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? 10X Genomics Inc trades at $81.97 (market cap $10.07B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.36 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 7.2× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| TXG | VCIT | |
|---|---|---|
Market Cap | $10.07B | $72.20B |
Volume | 5,657,286 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $97.74 | $84.82 |
52-Week Low | $11.48 | $77.98 |
Typical Hold Time | 92 Days | 61 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
VCIT trades at $78.345 with minimal daily movement (+0.1%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against peers. However, bearish technical signals and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors in current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
